Personne
Hristo Plamenov Varbanov
Cette personne n’est plus à l’EPFL
Publications associées (6)
Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis
Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov
Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...
2019Repositioning approved drugs for the treatment of problematic cancers using a screening approach
Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov
Advances in treatment strategies together with an earlier diagnosis have considerably increased the average survival of cancer patients over the last four decades. Nevertheless, despite the growing number of new antineoplastic agents introduced each year, ...
2017Oxaliplatin reacts with DMSO only in the presence of water
Paul Joseph Dyson, Laure Menin, Hristo Plamenov Varbanov
Herein we show that oxaliplatin reacts rapidly with DMSO in aqueous solutions, despite being stable in pure DMSO and pure water. Furthermore, the reactivity of the clinically applied Pt(II) drugs in water/DMSO and PBS/DMSO mixtures, and the nature of the s ...
2017The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs
Hristo Plamenov Varbanov, Sarah Theiner
The current study aims to elucidate the possible reasons for the significantly different pharmacological behavior of platinum(IV) complexes with cisplatin-, carboplatin- or nedaplatin-like cores and how this difference can be related to their main physicoc ...
Elsevier2016Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches
The octanol/water partition coefficient, logP, is one of the most important physico-chemical parameters for the development of new metal-based anticancer drugs with improved pharmacokinetic properties. This study addresses an issue with the absence of publ ...
Elsevier Science Inc2016Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy
A series of novel symmetrically and unsymmetrically coordinated platinum(IV) complexes with monodentate carboxylato ligands was synthesized. The compounds exhibit a general coordination sphere of [Pt(en)(OCOR)(2)(OCOR')(OCOR '')1, where the carboxylato lig ...
Elsevier Science Inc2015